Health Insurance & Pharmacy Benefit Management (Managed Care)
Strategic Profile
Cigna has recently reached a landmark FTC settlement in early February 2026 resolving a contentious lawsuit regarding insulin pricing, effectively ending years of litigation surrounding allegations that the company's pharmacy benefit manager Express Scripts manipulated drug formularies. The company secured regulatory stability by agreeing to overhaul business practices without admitting wrongdoing or paying direct financial penalties, though the agreement mandates a total transparency makeover requiring decoupling earnings from drug list prices—fundamentally altering the traditional PBM profit model.
Cyborg Score Rationale
Cigna exceeded Q4 2025 analyst expectations with adjusted EPS of $8.08 versus $7.87 forecasted and revenue of $72.5 billion versus $69.9 billion expected, while projecting 2026 adjusted EPS of at least $30.25. The FTC settlement removes significant regulatory overhang and positions the company for long-term stability, though margin compression from PBM structural reforms presents near-term headwinds.
Top Insights
The FTC settlement's mandated structural reforms are estimated to save American patients upwards of $7 billion in out-of-pocket costs over the next decade
Moving away from spread pricing and rebates will likely compress PBM margins throughout 2026 and 2027, with investors watching closely to see if the company can offset losses through increased volume and higher service fees
Strong performance is attributed to growth in the company's specialty pharmacy segment and innovative healthcare offerings
The company returned $5 billion to shareholders through dividends and share repurchases in 2025
Named Competitors
UnitedHealth Group — Largest integrated health insurer and pharmacy benefits manager
CVS Health — Major PBM and retail pharmacy competitor with Aetna integration
Humana — Medicare-focused managed care insurer
Anthem — Large regional and national health insurance provider
Recent Developments
(February 2026) FTC settlement resolving insulin pricing lawsuit with mandated PBM structural reforms effective for 10-year monitored agreement
(February 2026) Q4 2025 earnings beat with $72.5B revenue (vs $69.9B expected) and $8.08 EPS (vs $7.87 expected)
(February 2026) 2026 guidance of at least $30.25 adjusted EPS and $280B consolidated adjusted revenues; TD Cowen raised price target to $338
Open the full interactive The Cigna Group report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.